Fibrocell Science, Inc. Submits Clinical Study Report (CSR) to U.S. Food & Drug Administration for Phase II/III Trial of Azficel-T in Acne Scarring

Further Study Analysis in CSR Confirms Topline Results from
Clinical Trial
EXTON, Pa., Aug. 9 /PRNewswire-FirstCall/ -- Fibrocell Science,
Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on
the development of autologous cell...